Does not appear to be any update for the sepsis or Covid/Flu A/Flu B space in the Report. That concerns me, as the life sciences update seems to be more geared towards to acquisitions rather than development of new tests.
EDIT: "Cessation and realignment of resources from existing clinical developments (COVID-19, Multiplex, PCT) to assay development, due to regulatory and market conditions."
